Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618925 · ClinicalTrials.gov registry record · Phase 1
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
A Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05618925: Recruiting Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed, sponsored by ImmunityBio.
NCT05618925 is a Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05618925, a Phase 1 study of Non Hodgkin's Lymphoma Refractory/Relapsed, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.
Primary Outcome
Safety of CD19 t-haNK will be assessed by incidence and severity of TEAEs and SAEs, as well as incidence of clinically significant in safety laboratory tests and vital signs
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG N803
- BIOLOGICAL CD19t-haNK suspension
Study Locations (2)
California
- Hoag Memorial Hospital - Newport Beach
Texas
- Texas Oncology - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 1 |
What NCT05618925 shows while recruiting
NCT05618925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Non Hodgkin's Lymphoma Refractory/Relapsed appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05618925 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT05618925 about?
NCT05618925 is a clinical study titled "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma". Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects...
What is the current status of trial NCT05618925?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-08-22. Estimated completion is 2027-03-15.
What conditions does trial NCT05618925 study?
This clinical trial studies the following conditions: Non Hodgkin's Lymphoma Refractory/Relapsed.
What interventions are being tested in trial NCT05618925?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), N803 (DRUG), CD19t-haNK suspension (BIOLOGICAL).
Who is sponsoring clinical trial NCT05618925?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05618925 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05618925's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI